Scandinavian Real Heart

Bolag

Scandinavian Real Heart

Scandinavian Real Heart är verksamt inom medicinteknik. Bolaget bedriver forskning och utveckling inom observationer av hjärtats fysiologi. Utvecklingen av bolagets produkt, ett komplett artificiellt hjärta, sker i samarbete med hjärtkirurger, forskare och ingenjörer. Fokus ligger på att utveckla patenterade lösningar som kan imitera det naturliga mänskliga hjärtats blodcirkulation, med mål att användas av patienter som diagnostiserats med hjärtsvikt. Bolaget grundades år 2007.

Senaste publicering

I databasen

32 publicerade PM

Webbplats

Besök bolagets sida

Senaste nyheter och pressmeddelanden

12 visade
HEART

Peer-Reviewed Study Shows Six Times Lower Blood Damage in Realheart® TAH Than Market-Leading Device in Vitro

Västerås, Sweden, September 16, 2026 – Scandinavian Real Heart AB (publ) announces today that a study sponsored by the company has been published in the peer-reviewed journal Nature Scientific Reports, showing that the Realheart® TAH causes about six times less blood damage (hemolysis) than the only FDA-approved artificial heart device currently in wide clinical use. The study was carried out in a lab-based system mimicking full body circulation. Further, the study shows that the Realheart® TAH preserves a protein essential for blood coagulation and the prevention of internal bleeding.

HEART

Realheart Granted Patent Approval in Australia

Västerås, Sweden, June 28, 2026 – Scandinavian Real Heart AB (publ) today announced that IP Australia, the Australian intellectual property rights agency, has granted Realheart a patent covering central aspects of the Realheart® TAH technology. The granted claims include the design and operation of the total artificial heart, as well as the integrated feedback mechanism that regulates the device's cardiac output. The patent remains in force in Australia until 2041.

HEART

Peer-Reviewed Article Shows Superior Hemolysis Profile in Realheart® TAH Compared to Market-Leading Device

Västerås, Sweden, April 21, 2026 – Scandinavian Real Heart AB (publ) announces today that a new in vitro study, published in the peer-reviewed journal Artificial Organs, demonstrates that the Realheart® TAH causes approximately half the level of hemolysis – the mechanical destruction of red blood cells – compared with the only FDA-approved artificial heart device currently in wide clinical use. The differences across all primary endpoints were statistically significant (p < 0.05).